Search results for "type"

showing 10 items of 10618 documents

Cost-effectiveness of sofosbuvir plus ribavirin with or without pegylated interferon for the treatment of chronic hepatitis C in Italy.

2015

Objective:Across Italy up to 7.3% of the population is infected with hepatitis C virus (HCV), with long-term complications resulting in high medical costs and significant morbidity and mortality. Current treatment options have limitations due to side effects, interferon intolerability and ineligibility, long treatment durations and low sustained virological response (SVR) rates, especially for the most severe patients). Sofosbuvir is the first nucleotide polymerase inhibitor with pan-genotypic activity. Sofosbuvir, administered with ribavirin (RBV) and with or without pegylated interferon (PEG-INF), resulted in >90% SVR across treatment-naïve (TN) genotype (GT) 1-6 patients. It is also t…

medicine.medical_specialtySofosbuvirGenotypeCost effectivenessHepatitis C virusCost-Benefit AnalysisAlpha interferonmedicine.disease_causeGastroenterologyPolyethylene GlycolAntiviral AgentsSeverity of Illness IndexTelaprevirTelaprevirPolyethylene Glycolschemistry.chemical_compoundPegylated interferonBoceprevirInternal medicineQuality-Adjusted Life YearRibavirinmedicineCost-effectiveness analysiHumansCost-Benefit AnalysiAntiviral AgentBoceprevirbusiness.industryHealth PolicyRibavirinInterferon-alphaMarkov ChainHepatitis C ChronicPatient Acceptance of Health CareVirologyChronic hepatitis C infectionMarkov ChainschemistryItalyDrug Therapy CombinationQuality-Adjusted Life YearsSofosbuvirbusinessmedicine.drugHumanJournal of medical economics
researchProduct

Effect of Chronic Exercise Training on Blood Lactate Metabolism Among Patients With Type 2 Diabetes Mellitus : A Systematic Review and Meta-Analysis

2021

Purpose: To assess the effect of chronic exercise training on blood lactate metabolism at rest (i.e., basal lactate concentrations) and during exercise (i.e., blood lactate concentration at a fixed load, load at a fixed blood lactate concentration, and load at the individual blood lactate threshold) among patients with type 2 diabetes mellitus (T2DM).Methods: PubMed (MedLine), Embase, Web of Science, and Scopus were searched. Randomized controlled trials, non-randomized controlled trials, and case-control studies using chronic exercise training (i.e., 4 weeks) and that assessed blood lactate concentrations at rest and during exercise in T2DM patients were included.Results: Thirteen studies …

medicine.medical_specialtySports medicinePhysiologyT2DMbiomarkkerithyperlactatemialcsh:Physiologylaw.inventionchemistry.chemical_compoundphysical trainingaineenvaihduntahäiriötRandomized controlled triallawPhysiology (medical)medicineaineenvaihduntasystemaattiset kirjallisuuskatsauksetlcsh:QP1-981sports medicinebusiness.industrykuntoliikuntaLactate thresholdmeta-analyysilactic acidType 2 Diabetes Mellituslactate thresholdlaktaatitLactic acidBasal (medicine)chemistryAnesthesiaMeta-analysisHyperlactatemiaSystematic Reviewbusinessaikuistyypin diabetesfysiologiset vaikutukset
researchProduct

A low threshold to ECG-gated repeat CTA reduces the risk of false-positive diagnosis of type A dissection in interhospital referrals: a case series s…

2018

Angela Kornberger,1 Iris Burck,2 Hazem El Beyrouti,1 Nancy Halloum,1 Andres Beiras-Fernandez,1 Christian-Friedrich Vahl1 1Department of Cardiothoracic and Vascular Surgery, University Hospital of Johannes Gutenberg University, Mainz, Germany; 2Department of Diagnostic and Interventional Radiology, University Hospital of Johann Wolfgang Goethe University, Frankfurt am Main, Germany Background: False-positive diagnosis of acute Stanford type A aortic dissection (AAD) on computed tomography angiography (CTA) is still an issue and may lead to substantial consequences. Given that electrocardiography (ECG)-gated CTA provides greater diagnostic safety, it may be assumed that interhospital referral…

medicine.medical_specialtyStanford type A dissectionTherapeutics and Clinical Risk Managementfalse-positive diagnosisECG-gated CTA030204 cardiovascular system & hematology030218 nuclear medicine & medical imaging03 medical and health sciences0302 clinical medicinemedicinePharmacology (medical)Case Seriescardiovascular diseasesGeneral Pharmacology Toxicology and PharmaceuticsType a dissectionComputed tomography angiographyAortic dissectionChemical Health and Safetymedicine.diagnostic_testbusiness.industrymusculoskeletal neural and ocular physiologyGeneral Medicinemedicine.diseaseRadiologybusinessSafety ResearchElectrocardiographypsychological phenomena and processesCase seriesTherapeutics and Clinical Risk Management
researchProduct

Statin intolerance: new data and further options for treatment

2021

Purpose of review Hypercholesterolemia is a major risk factor for cardiovascular diseases. Administration of statins represents the cornerstone of the prevention and treatment of cardiovascular disease, with demonstrated long-term safety and efficacy. This review aims to revisit statin intolerance mechanisms, as well as to discuss new data and therapeutic options. Recent findings Although statins are well tolerated, myopathy and other adverse effects are a challenging problem, being the main reason for poor adherence to treatment and failure in lowering cardiovascular risk. Statin intolerance is the subject of ongoing research, as these drugs are widely used. There are alternative options o…

medicine.medical_specialtyStatinDosemedicine.drug_classHypercholesterolemiaDisease030204 cardiovascular system & hematology03 medical and health scienceschemistry.chemical_compound0302 clinical medicineEzetimibeHumansMedicinecardiovascular diseases030212 general & internal medicineRisk factorIntensive care medicineAdverse effectbusiness.industryCholesterolAnticholesteremic Agentsangiopoietin-like 3 protein inhibitors bempedoic acid ezetimibe proprotein convertase subtilisin-kexin type 9 inhibitors statin intolerance Cholesterol LDL Ezetimibe Humans Proprotein Convertase 9 Anticholesteremic Agents Cardiovascular Diseases Hydroxymethylglutaryl-CoA Reductase Inhibitors Hypercholesterolemianutritional and metabolic diseasesCholesterol LDLEzetimibeRegimenchemistryCardiovascular Diseaseslipids (amino acids peptides and proteins)Hydroxymethylglutaryl-CoA Reductase InhibitorsProprotein Convertase 9Cardiology and Cardiovascular Medicinebusinessmedicine.drug
researchProduct

Liraglutide reduces plasma PCSK9 in patients with type 2 diabetes not treated with statins

2022

Dyslipidaemia in type 2 diabetes mellitus (T2DM), which increases cardiovascular risk, includes abnormal metabolism of low-density lipoproteins (LDL). Our group has recently shown that liraglutide increases LDL catabolism in patients with T2DM and that it reduces the expression of PCSK9 (a major inhibitor of LDL-receptor expression) in vitro and in mice. This prompted us to study the effect of liraglutide on plasma PCSK9 level in patients with T2DM.We studied prospectively 82 patients with T2DM (51 without statins, 31 with statins). Plasma PCSK9 and plasma lipids were measured before and six months after the initiation of a treatment with liraglutide at a dose of 1.2 mg/day.Plasma PCSK9 was…

medicine.medical_specialtyStatinendocrine system diseasesmedicine.drug_classEndocrinology Diabetes and MetabolismType 2 diabetesMiceEndocrinologyDiabetes mellitusInternal medicineInternal MedicinemedicineAnimalsHumansGlycated HemoglobinCatabolismbusiness.industryLiraglutidePCSK9nutritional and metabolic diseasesType 2 Diabetes MellitusGeneral MedicineMetabolismLiraglutidemedicine.diseaseEndocrinologyDiabetes Mellitus Type 2lipids (amino acids peptides and proteins)Hydroxymethylglutaryl-CoA Reductase InhibitorsProprotein Convertase 9businessmedicine.drugDiabetes & Metabolism
researchProduct

Consenso Delphi sobre el manejo de la dislipidemia en pacientes con alteración del metabolismo de la glucosa: estudio Diana

2016

Objectives The aim of the present study was to develop a multidisciplinary consensus based on the Delphi system to establish clinical recommendations for the management of dyslipidaemia when hyperglycaemia is present, and the relevant factors that should be taken into consideration when prescribing and monitoring treatment with statins. Methods The questionnaire developed by the scientific committee included four blocks of questions about dyslipidaemia in patients with impaired glucose metabolism. The results of the first two blocks are presented here: a) management of dyslipidaemia; b) relevant factors that should be taken into consideration when prescribing and monitoring treatment with s…

medicine.medical_specialtyStatinmedicine.drug_classbusiness.industryType 2 Diabetes MellitusDisease030204 cardiovascular system & hematologymedicine.disease03 medical and health sciences0302 clinical medicineEndocrinologyInternal medicineDiabetes mellitusmedicinePharmacology (medical)030212 general & internal medicineRisk factorFamily historymedicine.symptomCardiology and Cardiovascular MedicineIntensive care medicinebusinessMass screeningAbdominal obesityClínica e Investigación en Arteriosclerosis
researchProduct

GLP-1 receptor agonists in NAFLD.

2017

IF 4.101; International audience; Non-alcoholic fatty liver disease (NAFLD) is very common in patients with type 2 diabetes (T2D), with approximately two-thirds having a diagnosis of the disease. Currently, the only validated treatment for NAFLD is weight loss. A number of studies of animal models and human trials have evaluated the effects of glucagon-like peptide-1 receptor agonists (GLP-1RAs) on liver fat content and suggest that the treatment could represent a new alternative for NAFLD management. In this review, our focus is on the main studies regarding the effects of GLP-1RAs on NAFLD. Also, the mechanisms that might explain their beneficial effects on liver diseases are analyzed.

medicine.medical_specialtySteatosisEndocrinology Diabetes and Metabolism030209 endocrinology & metabolismDiseaseType 2 diabetesGastroenterologyGlucagon-Like Peptide-1 Receptor03 medical and health sciences0302 clinical medicineEndocrinologyFibrosisWeight lossInternal medicineInternal MedicineHumansHypoglycemic AgentsMedicineReceptorGlucagon-like peptide 1 receptorGLP-1 receptor agonistsbusiness.industryFatty livernutritional and metabolic diseasesGeneral Medicine[ SDV.MHEP.EM ] Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolismmedicine.diseaseFibrosisdigestive system diseasesTreatment OutcomeDiabetes Mellitus Type 2030211 gastroenterology & hepatologytype 2 diabetesSteatosismedicine.symptombusinessNon-alcoholic fatty liver disease
researchProduct

Effects of BIS076 in a model of osteoarthritis induced by anterior cruciate ligament transection in ovariectomised rats

2015

Background Osteoarthritis (OA) is the most frequent articular disease and a leading cause of disability. There is a need for effective treatments able to slow the progression of disease. Some of the available treatments are dietary supplements providing natural components. Recent studies have shown that estrogen deficiency contributes to the pathophysiological events of OA progression. Methods We have used the anterior cruciate ligament transection model of OA in ovariectomised rats to study the effects of BIS076, a new formulation of a natural porcine cartilage extract associated with hydroxyapatite (as a source of calcium) and vitamin D3. Cartilage degradation, proteoglycan depletion and …

medicine.medical_specialtySwineOvariectomyType II collagenOsteoarthritisCartilage Oligomeric Matrix ProteinBIS076DinoprostoneBone remodelingRheumatologyOsteoprotegerinInternal medicineOsteoarthritismedicineAnimalsOrthopedics and Sports MedicineRats WistarVitamin DCollagen Type IIGlycosaminoglycansBone mineralCartilage oligomeric matrix proteinbiologybusiness.industryTissue ExtractsCartilageAnterior Cruciate Ligament InjuriesArticular cartilage damageOsteoarthritis Kneemedicine.diseasePeptide FragmentsSurgeryRatsDisease Models Animalmedicine.anatomical_structureEndocrinologyDurapatiteTreatment Outcomebiology.proteinAnterior cruciate ligament transection modelCytokinesFemaleMatrix Metalloproteinase 3businessOvariectomised ratsBiomarkersResearch ArticleBMC Musculoskeletal Disorders
researchProduct

Renal artery denervation for treating resistant hypertension: Definition of the disease, patient selection and description of the procedure

2012

Arterial hypertension is responsible for a significant burden of cardiovascular morbidity and mortality, worldwide. Although several rational and integrated pharmacological strategies are available, the control of high blood pressure still remains largely unsatisfactory. Failure to achieve effective blood pressure control in treated hypertensive patients may have a substantial impact on individual global cardiovascular risk, since it significantly increases the risk of developing hypertension-related macrovascular and microvascular complications. Arterial hypertension is arbitrarily defined as 'resistant' or 'refractory' when the recommended blood pressure goals (clinic blood pressure below…

medicine.medical_specialtySympathetic nervous systemSettore MED/09 - Medicina InternahypertensionDrug ResistanceFemoral arteryRisk AssessmentNephropathyPharmacotherapyRenal ArteryRisk Factorsmedicine.arteryInternal medicinemedicineInternal MedicineHumansArterial PressureRenal arterySympathectomyrenal artery denervationglobal cardiovascular riskantihypertensive therapyAntihypertensive AgentsSettore MED/14 - NefrologiaDenervationrefractory hypertensiontreatmentbusiness.industryPatient SelectionType 2 Diabetes Mellitusresistant hypertensionmedicine.diseaseSettore MED/11 - Malattie Dell'Apparato Cardiovascolaremedicine.anatomical_structureBlood pressureTreatment Outcomeresistant hypertension refractory hypertension renal artery denervation antihypertensive therapy global cardiovascular risk.resistant-hypertension; treatment; hypertensionCardiologyCatheter AblationHypertension treatment; Resistant-hypertension treatment; Antihypertensive Agents; Humans; Hypertension; Patient Selection; Renal Artery; Risk Assessment; Risk Factors; Sympathectomy; Treatment Outcome; Arterial Pressure; Catheter Ablation; Drug Resistance; Internal Medicine; Cardiology and Cardiovascular MedicinebusinessCardiology and Cardiovascular Medicineresistant-hypertension
researchProduct

Retarded thymic involution and massive germinal center formation in NF-ATp-deficient mice.

1998

NF-ATp and NF-ATc are the most prominent nuclear NF-AT transcription factors in peripheral T lymphocytes. After T cell activation both factors bind to and control the promoters and enhancers of numerous lymphokine and receptor ligand genes. In order to define a specific role for NF-ATp in vivo we have inactivated the NF-ATp gene by gene targeting in mice. We show that NF-ATp deficiency leads to the accumulation of peripheral T cells with a “preactivated” phenotype, enhanced immune responses of T cells after secondary stimulation in vitro and severe defects in the proper termination of antigen responses, as shown by a reduced deletion of superantigen-reactive CD4+ T cells. These alterations …

medicine.medical_specialtyT cellT-LymphocytesImmunologyApoptosisThymus GlandBiologyPolymerase Chain ReactionMiceImmune systemAntigenInternal medicinemedicineImmunology and AllergyCytotoxic T cellAnimalsfas ReceptorDNA PrimersMice KnockoutThymic involutionSuperantigensBase SequenceNFATC Transcription FactorsLymphokineGerminal centerNuclear ProteinsGerminal CenterMolecular biologyDNA-Binding ProteinsEndocrinologymedicine.anatomical_structureLymphatic systemPhenotypeTranscription FactorsEuropean journal of immunology
researchProduct